<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567671</url>
  </required_header>
  <id_info>
    <org_study_id>UVX-001</org_study_id>
    <nct_id>NCT00567671</nct_id>
  </id_info>
  <brief_title>Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia</brief_title>
  <acronym>CL</acronym>
  <official_title>Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, single site study to determine the safety and effectiveness of
      performing corneal collagen cross-linking (CCCL)using riboflavin and UVA light in eyes with
      corneal ectasia or progressive keratoconus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are randomized to a control group or a treatment group, with the control group
      crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is
      performed as a single treatment. Subjects are followed for at least 12 months to evaluate the
      long term effects of corneal collagen cross-linking.

      Subjects may be referred from other physicians but must return to Emory Vision for completion
      of all study visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in keratometry</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best spectacle-corrected visual acuity</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Progressive Keratoconus</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corneal collagen cross-linking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corneal collagen</intervention_name>
    <description>Corneal collagen cross-linking with riboflavin/UVA light</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham comparator</intervention_name>
    <description>Sham treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of keratoconus with documented progression over the previous 12 months.

          -  Diagnosis of corneal ectasia

          -  Must be able to complete all study visits

        Exclusion Criteria:

          -  Prior corneal surgery in the keratoconus group

          -  Corneal scarring
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Doyle Stulting, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory Vision; Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.emoryvision.com</url>
    <description>Click here to contact the investigator site for this study.</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>R. Doyle Stulting, MD, PhD., Professor of Ophthalmology, Emeritus, Principle Investigator</name_title>
    <organization>Woolfson Eye Intitute</organization>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>ectasia</keyword>
  <keyword>cross-linking</keyword>
  <keyword>riboflavin</keyword>
  <keyword>UVA light</keyword>
  <keyword>cornea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 1, 2013</submitted>
    <returned>November 30, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

